Valeant shares fall as Ackman exit highlights company’s challenges

March 14, 2017 By Svea Herbst-Bayliss and Michael Flaherty BOSTON (Reuters) – Valeant Pharmaceuticals Inc’s stock price fell to its lowest level in eight years on Tuesday after the abrupt exit of its biggest supporter put renewed focus on the Canadian company’s most pressing problem: raising capital to cut its roughly $30 billion debt pile. Billionaire investor William Ackman spent more than a year trying to revive Valeant’s stock price by helping to overhaul management, refresh the company’s board, and push for asset sales. But in a surprise move announced…

Read More